北京若生智能科技有限公司
Drug Database
SU

sumatriptan succinate (sc) (DFN 11 / Zembrace SymTouch / DFN11)

✓ Approved

Upsher-Smith Laboratories, LLC. · HTR1B · 小分子

什么是 sumatriptan succinate (sc)？

sumatriptan succinate (sc) 是一种小分子，由Upsher-Smith Laboratories, LLC.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名DFN 11, Zembrace SymTouch, DFN11
公司Upsher-Smith Laboratories, LLC.
药物类别小分子
分子靶点HTR1B, HTR1D
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Upsher-Smith Laboratories, LLC.

作用机制

分子靶点

sumatriptan succinate (sc) 作用于 2 个分子靶点：

HTR1B5-hydroxytryptamine receptor 1B (HTR1DB, 5-HT1DB)
HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sumatriptan succinate (sc) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersMigraine✓ Approved

相关研究文献

PubMedTherapeutic advances in neurological disorders2026-09-10

Use of subcutaneous natalizumab in routine care - Final results of a non-interventional, observational study (SISTER) in Germany and Austria.

Gold Ralf R, Schmidt Stephan S, Deisenhammer Florian F, Motte Jeremias J et al.

Natalizumab is a disease-modifying therapy for patients with relapsing-remitting multiple sclerosis (RRMS). In addition to its original intravenous (IV) formulation, a subcutaneous (SC) route of administration (RoA) was approved in 2021. Subsequently, the observational SISTER study was initiated in Germany and Austria to generate real-world data on the utilization, patient preferences, safety, and effectiveness of natalizumab in everyday clinical practice. The primary objective was to compare patients' preference of RoA and satisfaction with SC vs. IV natalizumab at baseline and up to 12 months of treatment. Secondary objectives included drug utilization, effectiveness outcomes, safety, and treatment satisfaction with natalizumab. SISTER was a prospective, multicenter, observational study on RRMS patients who were allocated to 3 parallel treatment cohorts: Patients switching from IV to SC natalizumab (SC switcher) and patients starting natalizumab on either the SC or IV route (starter SC/IV). The final study analyses were based on 310 patients (220 switchers, 44 SC starters, 46 IV starters) with an observation period of 10.8±3.1 months. Patient preference for the initial RoA at baseline was 95.1% among SC starters and 77.5% among IV starters (p=0.045). More IV starters than SC starters or SC switchers at baseline and Month 6 wished to change the initial RoA. Disease activity remained low in all cohorts, and the AE pattern was consistent with the known safety profile of natalizumab. The procedure duration was distinctly shorter on SC treatment than on IV treatment. The final SISTER results suggest a patient preference for the SC vs. IV route and support the outcomes of the NOVA Part 2 trial, in which the preference of the SC route over IV was demonstrated in a cross-over design. The SC route allowed relevant time savings, and its good safety and tolerability argues for possible self-administration of SC natalizumab.

PMID 42719433
阅读全文 →
PubMedCase reports in psychiatry2026-09-10

Clinical Consequences of Inadvertent Intramuscular Administration of Subcutaneous Risperidone Formulation.

Ashley Emma E, Aalomerovic Arnela A, Blackmer Kyle K, El-Mallakh Rif S RS

Long-acting injectable (LAI) antipsychotics have been predominately administered intramuscularly (IM). Recently, subcutaneous (SC) formulations have been developed. Information regarding what occurs when the drug is not administered properly is lacking. A 23-year-old woman with bipolar disorder, currently manic with psychosis, was responding well to a combination of lithium and risperidone. She accepted a LAI of SC risperidone, but the drug was administered IM by error. The improvement she had already displayed was partially lost, and oral risperidone had to be reinitiated. She complained of mild pain at the injection site, but no other adverse consequences were noted. When a SC formulation is administered IM, it results in mild muscle pain, and unpredictable release of risperidone, but no other notable clinical problems.

PMID 42719610
阅读全文 →
PubMedExperimental and therapeutic medicine2026-09-10

Retrospective study of infusion-related reactions in subcutaneous daratumumab administration in Japan.

Ino Yoko Y, Tanaka Kazuhide K, Ito Fuka F, Yamagishi Nao N et al.

The subcutaneous formulation of daratumumab (DARA-SC), an improved version of the intravenous formulation, has reduced administration time compared to the latter. However, real-world data regarding its infusion-related reactions (IRRs) remain limited. The present study evaluated the incidence rate, timing and risk factors for IRRs associated with the first dose of DARA-SC. This retrospective analysis included 65 patients who received their first DARA-SC dose at Gifu Municipal Hospital, Japan between May 2021 and June 2024. IRRs occurred in 10 patients (15.4%), and all cases were mild, categorized as grade 1 or 2. The median time to IRR onset was 10 h (range, 0.5-46 h), and delayed-onset IRRs (occurring after 24 h) accounted for 30% of cases. Univariate analysis identified a history of allergies as a potential factor associated with IRR occurrence (P=0.04). Older patients (≥70 years) tended to experience delayed-onset IRRs. Although these findings should be interpreted cautiously because of the limited cohort size, careful monitoring during initial DARA-SC administration might be important, particularly in patients with a history of allergies and in older patients, considering the possibility of delayed-onset IRRs.

PMID 42719041
阅读全文 →
PubMedAAPS PharmSciTech2026-09-10

An Assessment of In Vitro Permeation Testing Finite Dose Methodology.

Zhang Jerry J, Osborne David W DW

Pharmaceutical emulsifiers used in topical products are either non-ionic surfactants or anionic surfactants. Non-ionic emulsifiers are preferred because they minimally extract epidermal lipids from the stratum corneum (SC) and are well tolerated when applied topically. During topical vehicle development, the Franz diffusion cell allows investigators to determine the amount of drug delivered across the SC after topical application. In this study, we characterized extraction and permeation of 10 naturally occurring SC lipids in excised human skin loaded on a Franz cell 24 h after treatment with 4% sodium lauryl sulfate (SLS) aqueous solution versus neat water. Dermatomed human skin was loaded onto vertical Franz cells and chambers were filled with 0.9% NaCl solution. A 7.5-µL dose of water or 4% SLS aqueous solution was added to each Franz cell. Samples were tape stripped, collected, combined, and extracted with 2.0 mL of 1-hexanol/isopropanol/isopropyl myristate/N-methyl-2-pyrrolidone (15/25/20/40 by volume) overnight at 32°C on an orbit shaker. All 10 lipids were recovered from skin in sufficient amounts to be quantitated by liquid chromatography tandem mass spectrometry. Similar amounts of epidermal lipids were extracted from dermis, epidermis, and SC 24 h after dosing with water or 4% SLS, despite varying demographics of the three donors. For the 10 SC lipids characterized in this study, only ceramides showed lag times for appearing in receptor solution of the Franz cells. This study showed that ceramide NP and NS are suitable markers for epidermal lipid extraction after in vitro permeation testing using finite dosing of dermatomed human skin.

PMID 42717125
阅读全文 →
PubMedPest management science2026-09-10

Single-cell transcriptomic landscape of the southern green stink bug (Nezara viridula) midgut.

Arya Surjeet Kumar SK, Harrison Douglas A DA, Palli Subba Reddy SR

The southern green stink bug (SGSB), Nezara viridula, is a globally distributed hemipteran pest that damages many economically important crops. Its midgut supports digestion, defense, symbiosis, and interactions with orally delivered control agents, yet the cellular composition of this tissue remains poorly characterized. We therefore developed a single-cell transcriptomic atlas of the N. viridula midgut. Single-cell RNA sequencing of two biological replicates yielded a quality-filtered data set of 13,763 cells. Unsupervised clustering identified 12 transcriptionally distinct populations with putative annotations, including a stem cell/enteroblast (SC/EB)-like population, seven enterocyte-related populations, goblet-like cells, enteroendocrine cells, visceral muscle cells, and an extracellular-matrix-associated epithelial population. Enterocyte-related populations accounted for more than 77% of recovered cells. Putative annotations were assigned primarily from marker gene enrichment and homology to markers reported in other insects. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses identified population-associated functional enrichment patterns, and pseudotime analysis suggested transcriptional relationships between the SC/EB-like population and several enterocyte- and secretory-associated populations without establishing developmental lineages. Immune- and defense-associated transcripts were preferentially enriched in the pEC2 population, and genes associated with symbiont recognition, insecticide action, xenobiotic transport, and orally delivered double-stranded RNA showed population-biased expression. Descriptive comparisons with published insect midgut data sets identified shared and data-set-specific patterns among annotated populations. This atlas provides the first single-cell transcriptomic resource for a stink bug midgut and establishes a descriptive cellular framework for SGSB midgut biology. The dataset prioritizes candidate genes and cell populations for future spatial validation, functional testing, and studies of hemipteran midgut physiology, symbiosis, immunity, and pest-management-relevant traits. © 2026 Society of Chemical Industry.

PMID 42717362
阅读全文 →
PubMedChemistry & biodiversity2026-09-10

Synthesis and Antifungal Evaluation of Isoquinoline-3-amide Derivatives Containing a Phenoxypyridine Moiety for Plant Protection.

Zhang Jiayao J, Sun Shuaipeng S, Guo Yajing Y, Xu Zhiyuan Z et al.

To discover novel green antifungal candidates, 20 3-acylaminoisoquinoline derivatives were designed and synthesized by introducing the active fragment phenoxypyridine. Their structures were verified by 1H NMR, 13C NMR, and HRMS. The structure of compound X9 was further confirmed via X-ray crystallography. Their antifungal activities against five phytopathogenic fungi were evaluated to develop isoquinoline-based antifungal agents. Among them, compound X6 demonstrated significant antifungal activity against Botrytis cinerea with an EC50 value of 7.55 µg/mL. In vivo assays revealed that compound X6 exhibited strong protective and curative efficacy against B. cinerea with rates of 77.86% and 45.45% at a concentration of 100 µg/mL. Molecular docking studies confirmed that isoquinoline amide compounds possess strong binding affinity to succinate dehydrogenase (SDH). Molecular dynamics (MD) simulations revealed that compound X6 has better pocket spatial compatibility and more stable binding interactions with SDH than boscalid. Furthermore, SDH activity assays showed compound X6 inhibited SDH activity by 66.7% at 4 EC50 concentration, which was comparable to that of the boscalid (75.85%). These findings demonstrated that isoquinoline derivatives incorporating the phenoxypyridine fragment possess potent fungicidal properties for crop safety, with compound X6 emerging as a promising candidate for a novel SDH inhibitor.

PMID 42720078
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sumatriptan succinate (sc)